---
title: Breathing With a Facemask Exercise Performance
nct_id: NCT05633017
overall_status: COMPLETED
sponsor: CereVu Medical, Inc.
study_type: OBSERVATIONAL
primary_condition: Pulmonary Disease, Chronic Obstructive
countries: United States
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT05633017.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT05633017"
ct_last_update_post_date: 2025-10-15
last_seen_at: "2026-05-12T06:02:14.544Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Breathing With a Facemask Exercise Performance

**Official Title:** Measuring Exercise Performance and Perception With Facemask Resistance

**NCT ID:** [NCT05633017](https://clinicaltrials.gov/study/NCT05633017)

## Key Facts

- **Status:** COMPLETED
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 52
- **Lead Sponsor:** CereVu Medical, Inc.
- **Collaborators:** John Muir Health
- **Conditions:** Pulmonary Disease, Chronic Obstructive
- **Start Date:** 2022-11-29
- **Completion Date:** 2024-09-17
- **CT.gov Last Update:** 2025-10-15

## Brief Summary

This study will determine the dyspnea response in chronic lung disease volunteers during treadmill walking with and without added inspiratory resistance. This study will also determine the level of dyspnea and exercise sense of effort in individuals walking on a treadmill when elevations occur. Comparisons will be made of a participant's exercise response with and without increased inspiratory resistance. In this study, exercise performance will be analyzed based on physiological and perceptual measures. The participant will undergo two sessions: one session will be a standard exercise walking test without an inspiratory resistance; the other session will be the same standard exercise walking test while breathing with an inspiratory resistance equal to a N95 facemask (R=10-15 cmH2O/L/sec). Performance will be determined by physiological measures. Perception will be determined by scores based on numerical scales and automatically with the forehead Vitality remote monitoring sensor.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** Yes

```
Inclusion Criteria:

* Former pulmonary rehabilitation patients that are now participating in maintenance exercise classes
* Males and females with an age range of 18 years or older
* Subjects must be able to walk on treadmill for multiple sessions

Exclusion Criteria:

* The subjects in each experiment will be recruited for a distribution of gender, ethnicity and age
```

## Arms

- **Pulmonary Rehab Patients** — Patients who attend respiratory therapy at John Muir Pulmonary Rehab facility
- **Control** — Healthy adults, 18+

## Interventions

- **CereVu Objective Dyspnea Score** (COMBINATION_PRODUCT) — Small forehead wearable and mobile app

## Primary Outcomes

- **Correlation between dyspnea as measured by the device and reported dyspnea by subjects** _(time frame: 2 hours)_

## Locations (1)

- John Muir Health, Pleasant Hill, California, United States

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.john muir health|pleasant hill|california|united states` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT05633017.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT05633017*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*